AgroPages-Cellectis signed CRISPR/Cas9 licensing deal with University of Minnesota-Agricultural news

Cellectis Plant Sciences recently announced it has signed an exclusive licensing agreement with the University of Minnesota, granting the firm worldwide rights to patents covering the use of CRISPR/Cas9 technology in plants.

The technology, developed for genome engineering in plants by University of Minnesota Professor Dan Voytas, strengthens Cellectis' gene editing property rights, the firm said in a statement. Cellectis also has rights to use meganuclease and transcription activator-like effector nuclease-based gene editing technologies.

Applying CRISPR/Cas9 gene editing in plants could help scientists develop valuable crops, the firm said in a statement.
Financial and other details of the agreement were not disclosed.

Subscribe Email:		*
Name:
Mobile Number:

A Deep exploration into Regulatory Analysis, Join upcoming <2024 CROs & CRAOs Manual>Magazine

Join 2024 Formulation & Adjuvant Technology Magazine to Show Your Insights and Innovation SolutionsMagazine

BioEx 2024 successfully held: Biological innovation leading the way towards sustainable agricultureEvent

Cellectis signed CRISPR/Cas9 licensing deal with University of Minnesota

More from AgroNewsChange

Magazine

Hot Topic More

NEWSLETTER